Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• The pooled objective response rate (ORR) for KRAS (G12C) inhibitors, including sotorasib, was 28.6% (95 % confidence interval (CI), 21.2-36.6%), with a disease control rate (DCR) of 85.5% (95% CI, 82.2-88.6%). Sotorasib showed effectiveness in heavily pretreated patients with advanced KRAS(G12C)-mutated solid tumors.
• Progression-free survival (PFS) at 6 and 12 months was 49.6% (95% CI, 41.4-57.9%) and 26.7% (95% CI, 19.8-34.1%), respectively. The median duration of response (DoR) was 10.54 months (95% CI, 7.72-13.36 months), indicating sustained benefit in responding patients.
• In a specific subgroup with KRAS(G12C)-mutated non-small cell lung cancer (NSCLC) and KEAP1 co-mutation, the ORR was worse compared to patients with wild-type KEAP1 (odds ratio (OR): 0.35, 95% CI: 0.16-0.77), suggesting reduced effectiveness in this subgroup.
• The pooled incidence of any grade treatment-related adverse events (trAEs) for sotorasib was 79.3% (95% CI, 66.2-90.0%), with 24.4% (95% CI, 16.7-32.9%) experiencing grade three or more trAEs.
• Compared to adagrasib, sotorasib had significantly lower incidences of both any grade trAEs (OR, 0.07, 95% CI, 0.03-0.14) and grade three or more trAEs (OR, 0.34, 95% CI, 0.24-0.49).